Browse the corpus

Azilsartan is an angiotensin II receptor blocker used in the management of hypertension to reduce cardiovascular risk and protect against end-organ damage. By selectively inhibiting angiotensin II binding to the angiotensin II type 1 receptor, azilsartan causes vasodilation, reduces aldosterone secretion, and lowers blood pressure without significantly affecting heart rate. This activity explores the pharmacological properties of azilsartan, including its mechanism of action, pharmacokinetics, clinical indications, contraindications, and potential adverse effects. The course also reviews considerations for administration, off-label uses, and drug interactions that may influence therapeutic response. Understanding the pharmacology and safety profile of azilsartan enables healthcare professionals to select appropriate patients, tailor therapy to individual needs, and improve outcomes in the management of hypertension. Participants in this activity gain the ability to apply evidence-based principles to optimize azilsartan use in clinical practice. The course emphasizes identifying and managing adverse drug reactions, implementing appropriate monitoring strategies, and recognizing clinical scenarios in which azilsartan offers particular benefit or requires caution. Collaborative engagement among primary clinicians, nurses, pharmacists, and other healthcare professionals enhances treatment safety and continuity of care, ensuring accurate dosing, patient adherence, and early identification of complications. By strengthening communication and shared clinical decision-making within the interprofessional team, this course advances the collective goal of achieving effective blood pressure control and improving long-term cardiovascular outcomes. Objectives: Evaluate the mechanism of action of azilsartan. Identify the indications for azilsartan therapy. Assess the potential adverse effects and contraindications of azilsartan. Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from azilsartan therapy. Access free multiple choice questions on this topic.

Signs and Symptoms of Overdose Currently, there is no established maximum toxic dose for azilsartan. Patients on azilsartan with volume depletion, severe heart failure, or renal stenosis are at risk for oliguria or progressive azotemia.[2] Volume or salt depletion should be corrected first before initiating azilsartan.[2] According to the product labeling, during clinical trials involving healthy subjects, once-daily doses of up to 320 mg of azilsartan were well-tolerated over 7 days. Management of Overdose In the event of an overdose, supportive therapy should be administered in accordance with the patient's clinical condition. Symptomatic hypotension may necessitate treatment with intravenous fluids; refractory cases may require the use of vasopressors. Azilsartan is not removed through dialysis. For complex overdoses, healthcare professionals should contact the poison control center and consult a medical toxicologist to obtain current guidance and recommendations.

Although azilsartan is generally well-tolerated, the interprofessional team must understand the risks of co-prescribing ACE inhibitors, aliskiren-containing products, or other ARBs. Primary care clinicians should remain vigilant to prevent overlapping prescriptions when multiple team members manage a patient's care. Pharmacists are responsible for reviewing medication profiles for interactions, verifying dosing, alerting the team to potential adverse effects, and providing patient counseling. Nurses ensure that patient records accurately list all prescribed medications and the clinicians involved, supporting verification of drug interactions, duplicate therapies, and proper dosing. A study on pediatric hypertension demonstrated that clinician-pharmacist collaborative drug therapy management improved rates of achieving target blood pressure without increasing adverse events.[33] All team members must confirm that women of childbearing potential are not pregnant before initiating azilsartan or any ARB. Integrating electronic health record–guided prescribing with alerts, alongside structured interprofessional collaboration, enhances guideline-directed hypertension management, reduces the risk of hyperkalemia and renal injury, and improves adherence to monitoring protocols. Coordinated communication, dosing verification, patient education, and monitoring of adverse effects enable the healthcare team to optimize the safety and effectiveness of azilsartan therapy, ultimately improving patient outcomes.